Bioheart appoints new CEO
This article was originally published in Scrip
Executive Summary
Bioheart (US), a biotechnology company developing autologous (patient-derived) cell therapies and devices for the treatment of chronic and acute heart damage, has appointed Howard Leonhardt, Bioheart's co-founder, chairman of the board and chief technology officer, to serve as chief executive officer. This follows the resignation of William Pinon as the company's president and CEO, and as a member of the board of directors.